$17.45
2.46% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

ADMA Biologics, Inc. Stock price

$17.45
-4.38 20.06% 1M
+6.50 59.36% 6M
+12.93 286.06% YTD
+12.96 288.64% 1Y
+16.20 1,296.00% 3Y
+13.50 341.77% 5Y
+6.45 58.64% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.44 2.46%
ISIN
US0008991046
Symbol
ADMA
Sector
Industry

Key metrics

Market capitalization $4.13b
Enterprise Value $4.15b
P/E (TTM) P/E ratio 63.16
EV/FCF (TTM) EV/FCF 52.27
EV/Sales (TTM) EV/Sales 10.84
P/S ratio (TTM) P/S ratio 10.78
P/B ratio (TTM) P/B ratio 17.79
Revenue growth (TTM) Revenue growth 63.39%
Revenue (TTM) Revenue $382.81m
EBIT (operating result TTM) EBIT $114.89m
Free Cash Flow (TTM) Free Cash Flow $79.39m
Cash position $86.71m
EPS (TTM) EPS $0.28
P/E forward 34.90
P/S forward 9.77
EV/Sales forward 9.83
Short interest 5.30%
Show more

Is ADMA Biologics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

ADMA Biologics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a ADMA Biologics, Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a ADMA Biologics, Inc. forecast:

Buy
100%

Financial data from ADMA Biologics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
383 383
63% 63%
100%
- Direct Costs 196 196
20% 20%
51%
187 187
162% 162%
49%
- Selling and Administrative Expenses 62 62
7% 7%
16%
- Research and Development Expense 1.87 1.87
52% 52%
0%
123 123
1,196% 1,196%
32%
- Depreciation and Amortization 8.21 8.21
1% 1%
2%
EBIT (Operating Income) EBIT 115 115
8,473% 8,473%
30%
Net Profit 68 68
398% 398%
18%

In millions USD.

Don't miss a Thing! We will send you all news about ADMA Biologics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ADMA Biologics, Inc. Stock News

Neutral
GlobeNewsWire
9 days ago
Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA's Total Debt to $75 Million, a 29% Reduction Further Supports Earnings Growth Outlook RAMSEY, N.J. and BOCA RATON, Fla.
Positive
Seeking Alpha
27 days ago
ADMA Biologics is a rapidly growing player in plasma-derived therapies, with a 78% YoY revenue increase and a 1,300% YoY net income boost. The company's key product, ASCENIV, is expected to drive significant revenue growth and improve margins, supported by a completed pediatric trial and upcoming sBLA submission. Past legal controversies about an auditor's resignation caused temporary investor ...
Positive
Investors Business Daily
about one month ago
ADMA stock hit a new buy point in recent weeks after recovering from an unexpected plunge that sent shares below a key level. The post Biotech Leader ADMA Hits New Buy Point After Recovering From Surprise Plunge appeared first on Investor's Business Daily.
More ADMA Biologics, Inc. News

Company Profile

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.

Head office United States
CEO Adam Grossman
Employees 624
Founded 2004
Website www.admabiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today